Form 8-K - Current report:
SEC Accession No. 0001104659-24-112841
Filing Date
2024-10-31
Accepted
2024-10-31 06:44:02
Documents
17
Period of Report
2024-10-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2426878d1_8k.htm   iXBRL 8-K 41192
2 EXHIBIT 99.1 tm2426878d1_ex99-1.htm EX-99.1 470399
3 EXHIBIT 99.2 tm2426878d1_ex99-2.htm EX-99.2 585455
8 GRAPHIC tm2426878d1_ex99-1img001.jpg GRAPHIC 3257
  Complete submission text file 0001104659-24-112841.txt   1420295

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mrk-20241031.xsd EX-101.SCH 4849
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mrk-20241031_def.xml EX-101.DEF 29537
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrk-20241031_lab.xml EX-101.LAB 40219
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrk-20241031_pre.xml EX-101.PRE 28018
19 EXTRACTED XBRL INSTANCE DOCUMENT tm2426878d1_8k_htm.xml XML 12322
Mailing Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033
Business Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 908-740-4000
Merck & Co., Inc. (Filer) CIK: 0000310158 (see all company filings)

EIN.: 221918501 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-06571 | Film No.: 241412349
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)